Artiva Biotherapeutics, Inc.
ARTV
$5.52
-$0.28-4.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -83.87M | -79.19M | -75.13M | -71.72M | -65.37M |
| Total Depreciation and Amortization | 2.60M | 2.55M | 2.51M | 2.47M | 2.43M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.94M | 4.79M | 5.74M | 8.26M | 8.24M |
| Change in Net Operating Assets | -424.00K | -4.82M | -2.20M | 1.20M | -325.00K |
| Cash from Operations | -76.75M | -76.68M | -69.09M | -59.79M | -55.03M |
| Capital Expenditure | -2.59M | -2.23M | -1.73M | -1.14M | -642.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.00M | 48.64M | -98.78M | -119.14M | -119.82M |
| Cash from Investing | 63.41M | 46.41M | -100.50M | -120.27M | -120.46M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -132.00K | -131.00K | -137.00K | -182.00K | -149.00K |
| Issuance of Common Stock | 138.00K | 161.00K | 166.67M | 166.70M | 166.56M |
| Repurchase of Common Stock | -230.00K | -143.00K | -39.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 233.00K | 213.00K | -2.49M | -4.05M | -4.18M |
| Cash from Financing | 9.00K | 100.00K | 164.01M | 162.47M | 162.23M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.33M | -30.17M | -5.58M | -17.60M | -13.27M |